- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 213/87 - HydrazidesLeurs thio ou imino analogues en position 3
Détention brevets de la classe C07D 213/87
Brevets de cette classe: 39
Historique des publications depuis 10 ans
|
4
|
4
|
2
|
1
|
5
|
3
|
3
|
2
|
0
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| HMI Medical Innovations, LLC | 14 |
8 |
| Theravance Biopharma R&D IP, LLC | 362 |
3 |
| F. Hoffmann-La Roche AG | 7837 |
2 |
| Bayer Cropscience AG | 1844 |
2 |
| The General Hospital Corporation | 4870 |
2 |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 92 |
2 |
| Monash University | 733 |
2 |
| The Walter and Eliza Hall Institute of Medical Research | 166 |
2 |
| Mitsui Chemicals Agro, Inc. | 79 |
1 |
| Cytokinetics, Inc. | 251 |
1 |
| Eurofarma Laboratorios S.A. | 37 |
1 |
| Fudan University | 767 |
1 |
| Memorial Sloan-Kettering Cancer Center | 2043 |
1 |
| Musc Foundation for Research Development | 368 |
1 |
| Shandong University | 1152 |
1 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 873 |
1 |
| Shanghai Institute of Pharmaceutical Industry | 127 |
1 |
| Synta Pharmaceuticals Corp. | 145 |
1 |
| Universidade Federal do Rio de Janeiro-ufrj | 98 |
1 |
| University of Utah Research Foundation | 1862 |
1 |
| Autres propriétaires | 4 |